Keyword Suggestion
Domain Informations
Network
- inetnum : 35.208.0.0 - 35.247.255.255
- name : GOOGLE-CLOUD
- handle : NET-35-208-0-0-1
- status : Direct Allocation
- created : 2006-09-29
- changed : 2019-11-01
- desc : *** The IP addresses under this Org-ID are in use by Google Cloud customers ***,Direct all copyright and legal complaints to,https://support.google.com/legal/go/report,Direct all spam and abuse complaints to,https://support.google.com/code/go/gce_abuse_report,For fastest response, use the relevant forms above.,Complaints can also be sent to the GC Abuse desk,([email protected]),but may have longer turnaround times.,*** The IP addresses under this Org-ID are in use by Google Cloud customers ***,Direct all copyright and legal complaints to,https://support.google.com/legal/go/report,Direct all spam and abuse complaints to,https://support.google.com/code/go/gce_abuse_report,For fastest response, use the relevant forms above.,Complaints can also be sent to the GC Abuse desk,([email protected]),but may have longer turnaround times.,Complaints sent to any other POC will be ignored.
Owner
- organization : Google LLC
- handle : GOOGL-2
- address : Array,Mountain View,CA,94043,US
Abuse
- handle : GCABU-ARIN
- name : GC Abuse
- phone : +1-650-253-0000
- email : [email protected]
Technical support
- handle : ZG39-ARIN
- name : Google LLC
- phone : +1-650-253-0000
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 35.246.184.45
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Timezone: America/Los_Angeles
Site Inspections
Port Scanner (IP: 35.246.184.45)
Spam Check (IP: 35.246.184.45)
Recent Searched Sites
› Nastrax.com (0 seconds ago) / NL
› Pelisflix-k4yr.s3.amazonaws.com (11 seconds ago) / US
› Ync.tw (0 seconds ago) / US
› Kaiyuntimes.com (6 seconds ago) / HK
› Fabianedurao.com (6 seconds ago) / US
› Mailings.kas.de (0 seconds ago) / DE
› Cleobetracasino.casino (24 seconds ago) / US
› Chameleon-decorators.co.uk (9 seconds ago) / US
› Adn.art (0 seconds ago) / US
› Usuki-portal.herokuapp.com (1 seconds ago) / US
› Negevgas.co.il (6 seconds ago) / NL
› Wavyradio.co.uk (10 seconds ago) / DE
› B2clogistics.com (1 seconds ago) / AU
› Portal.medicscloud.com (6 seconds ago) / US
› En.orsiro.com (0 seconds ago) / US
› Ibizabus.com (24 seconds ago) / ES
› Americanvirtualacademy.com (0 seconds ago) / US
› Goalzaa.com (3 seconds ago) / US
› Nomio.laboral.medac.es (1 seconds ago) / IE
› Downloads.smartvisionlights.com (10 seconds ago) / US
Websites Listing
We found Websites Listing below when search with en.orsiro.com on Search Engine
Home | Orsiro
The safety and effectiveness of Orsiro and Orsiro Mission have not yet been established in patients with the following: In-stent restenosis. 3 vessel coronary disease. An unresolved thrombus at the lesion site. Coronary artery reference …
En.orsiro.comCONTACT - en.orsiro.com
Thank you for getting in touch with us! Please contact us using the form below and a BIOTRONIK team member will respond shortly. Please find our international BIOTRONIK contacts here.
En.orsiro.comContact | Orsiro US
Home Orsiro Mission DES Orsiro DES CLINICAL STUDIES NEWSROOM Contact EN Please select a country/region and language. Countries/Regions. United States of America; Languages. Confirm your selection . Search. Submit. CONTACT. Thank you for getting in touch with us! Please contact us using the form below and a BIOTRONIK team member will respond shortly. …
Us.orsiro.comGmail
We would like to show you a description here but the site won’t allow us.
Mail.google.comBIOSTEMI 2Y | Orsiro - en.orsiro.com
The safety and effectiveness of Orsiro and Orsiro Mission have not yet been established in patients with the following: In-stent restenosis. 3 vessel coronary disease. An unresolved thrombus at the lesion site. Coronary artery reference vessel diameters < 2.25 mm or > 4.0 mm. Lesion length > 36 mm. Chronic total occlusion (CTO).
En.orsiro.comACS - en.orsiro.com
The safety and effectiveness of Orsiro and Orsiro Mission have not yet been established in patients with the following: In-stent restenosis. 3 vessel coronary disease. An unresolved thrombus at the lesion site. Coronary artery reference vessel diameters < 2.25 mm or > 4.0 mm. Lesion length > 36 mm. Chronic total occlusion (CTO).
En.orsiro.comFull Cohort | Orsiro - en.orsiro.com
A Prospective, Randomized Three-Arm Trial Comparing Orsiro, Synergy and Resolute Integrity in an All-Comers Population; Presented at: TCT 2016; October 30, 2016; Washington DC, USA; ClinicalTrials.gov: NCT01674803; 3. von Birgelen C et al. 3-Years BIO-RESORT: Results of the 3-Arm randomized study in all-comers, treated with contemporary biodegradable or durable …
En.orsiro.comNEWSROOM | Orsiro US
Home Orsiro Mission DES Orsiro DES CLINICAL STUDIES NEWSROOM Contact EN Please select a country/region and language. Countries/Regions. United States of America; Languages. Confirm your selection. Search. Submit. NEWS ROOM HOME; PRESS RELEASES AND STATEMENTS; STORIES; Press Contact . Dr. Zara Barlas. Corporate Public Relations & …
Us.orsiro.comOrsiro - Biotronik
Orsiro is superior to Xience in STEMI patients undergoing primary PCI with respect to Target Lesion Failure (TLF) rate at 12 months. Long-term safety . In the randomized, all-comers BIOSCIENCE trial (n= 2,119) 5. Orsiro shows numerically equal or lower Stent Thrombosis (ST) in complex patients in comparison to Xience. * Compared to Xience, BIOTRONIK data on file, …
Biotronik.comorsiro - GitHub
Orsiro Follow. Overview Repositories 3 Projects 0 Packages 0 Stars 54. orsiro Follow. orsiro Follow. 1 follower · 0 following Block or Report Block or report orsiro. Block user. Prevent this user from interacting with your repositories and sending you notifications. Learn more about blocking users. You must be logged in to block users. ...
Github.comHeart | Orsiro US
As we get older, our risk for a variety of cardiovascular conditions increases. It’s a fact that likely doesn’t come as a big surprise to many people—but that doesn’t mean the discussions aging patients need to have with their families and doctors get any easier.
Us.orsiro.comOrsiro Mission - Animación - YouTube
Orsiro Mission está indicado para mejorar el diámetro luminal coronario en pacientes con enfermedad cardiaca isquémica sintomática debido a lesiones estenóti...
Youtube.comNEWSROOM | Orsiro US
2020-10-03 · Home Orsiro Mission DES Orsiro DES CLINICAL STUDIES NEWSROOM Contact EN Please select a country/region and language. Countries/Regions. United States of America; Languages. Confirm your selection. Search Submit. NEWS ROOM HOME; PRESS RELEASES AND STATEMENTS; STORIES; Press Contact . Dr. Zara Barlas. Corporate Public Relations …
Us.orsiro.comQuel est le meilleur stent actif - Réalités Cardiologiques
2021-02-05 · Dans une méta-analyse en réseau évaluant l’échec à 1 an de revascularisation de la lésion cible, parmi 4 stents actifs, le stent Orsiro est apparu significativement supérieur que les stents Xience, Nobori/BioMatrox et Resolute. Au terme d’un suivi de 50 mois, la différence s’estompe mais, globalement, le stent Orsiro reste supérieur aux autres stents.
Realites-cardiologiques.comOrsiro Mission gets CE mark - Cardiovascular News
2020-02-12 · Orsiro Mission is now available in CE mark countries. The press release outlines that the Orsiro Mission DES has a completely reengineered delivery system to support interventionalists with outstanding deliverability, even in challenging cases. The coating combines passive and active components to avoid interaction with surrounding tissue, while ensuring a …
Cardiovascularnews.comÉtude randomisée BIOFLOW-V - Cardiologie Pratique
Présentation du stent actif ORSIRO à polymère biodégradable. Méthodes BIOFLOW-V est une étude randomisée multicentrique qui a comparé le stent ORSIRO au stent XIENCE (2/1) dans le traitement des lésions des artères coronaires. Les patients ont été inclus dans 90 hôpitaux et 13 pays en Asie, Europe, Israël et Amérique du Nord.
Cardiologie-pratique.comOrsiro archivos | SOLACI
37th Annual Meeting of the Uruguayan Society of Cardiology: Registration Waiver for SOLACI Members! - 21 / 05 / 2021
Solaci.orgBIOTRONIK Newsroom - Newsroom BIOTRONIK
These data reinforce the body of evidence differentiating Orsiro ... For any questions, please do not hesitate to contact your local BIOTRONIK representative or email us at [email protected]. BIOTRONIK Statement on the Log4Shell Vulnerability . The vast majority of strokes—about 85 percent—are ischemic. Of these, up to a third are cryptogenic, or have no clear cause. Getting …
News.biotronik.comOrsiro : le stent hybride | WedelaTV
2015-01-12 · Si la vidéo ne s'affiche pas cliquez ici Découvrez Orsiro, nouveau stent mis au point par Biotronik. Sur ce stent actif dernière génération, le polymère qui libère progressivement le médicament se résorbe au fil des premiers mois après la pose. Explications du principe et des enjeux avec le Pr Didier Carrié.
Wedelatv.wordpress.comBIOTRONIK Wins FDA Approval for Orsiro Coronary Stent ...
2019-03-06 · Orsiro is designed for use in PCI procedures, where the cobalt chromium metal stent elutes sirolimus via BIOTRONIK’s bioresorbable polymer coating, dubbed BIOlute™. Beneath this layer is a passive coating of BIOTRONIK’s proBIO™, which is designed to reduce nickel iron release. Orsiro boasts ultrathin stent struts while maintaining radial strength and a …
Idataresearch.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| weconnectllc.com | godaddy.com | 5 Years, 196 Days |
| meadpl.org | whois.godaddy.com | 340 Days |
| velaspa.com | register.it | -3 Years, -33 Days |
| rru.ac.in | ernet.in | 4 Years, 90 Days |
| americanphotographic.com | namecheap.com | -3 Years, -189 Days |
| myfuture.net | networksolutions.com | -2 Years, -118 Days |
| shebaagency.com | opentld.com | -3 Years, -312 Days |
| fsocium.com | nic.ru | -3 Years, -265 Days |
| dniletra.com | namecheap.com | -3 Years, -313 Days |
| telugumovies.com | godaddy.com | -3 Years, -275 Days |